Key Highlights
- Harry S. Palmin appointed as CFO of Anumana and nference, enhancing leadership in health tech.
- Anumana’s ECG-AI™ technology receives FDA clearance for LEF detection, marking significant advancements in cardiology.
- Collaborations with top pharmaceutical companies accelerate development and commercialization of AI-driven diagnostic tools.
Source: Business Wire
Notable Quotes
- “Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” – Maulik Nanavaty, CEO at Anumana
- “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring,” – Harry S. Palmin, CFO at Anumana
SoHC's Take
Harry S. Palmin’s extensive background in finance and operations in the life sciences sector is a strategic addition to Anumana, especially at a juncture where the company is pushing the boundaries of AI in cardiology. His dual role at Anumana and nference is likely to harmonize the financial and developmental strategies across both platforms, potentially leading to accelerated growth and more innovative breakthroughs in healthcare technology. As Anumana continues to forge key partnerships and gain regulatory approvals, Palmin’s expertise will be crucial in steering the company towards a future where AI and healthcare intersect more seamlessly.
